title: Evaluation of compound activity against hepatitis C virus in replicon systems.
abstract: Described in this unit are protocols for evaluation of new chemical entities for activity against hepatitis C virus (HCV) using HCV replicon systems. While agents designed to target NS3 protease, NS3 helicase, and NS5B RNA polymerase can be evaluated in biochemical assays, it is important to confirm their inhibitory effect on HCV RNA replication using HCV replicon systems, especially since replication involves many components besides these enzymes. Screening of compound libraries using replicon systems has led to the discovery of replication inhibitors, which act through different viral targets.
authors.affiliation: Achillion Pharmaceuticals, New Haven, Connecticut, USA.
authors.forename: Guangwei
authors.initials: G
authors.lastname: Yang
authors.forename: Mingjun
authors.initials: M
authors.lastname: Huang
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001681:Biological Assay / Q000379:methods*; D023381:Endpoint Determination; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology; D015151:Immunoblotting / Q000379:methods; D008156:Luciferases / Q000378:metabolism; D012367:RNA, Viral; D012093:Replicon; D013048:Specimen Handling / Q000379:methods; D013223:Statistics as Topic; D014162:Transfection / Q000379:methods; D014779:Virus Replication / Q000502:physiology*
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; C052835:adenovirus associated RNA; D008156:Luciferases